Smoking, older age put patients receiving tofacitinib at higher risk for MACE vs. TNFi

Patients aged 65 years and older or who have ever smoked are at higher risk for malignancies, major adverse cardiovascular events, myocardial infarction and all-cause death when using tofacitinib vs. TNF inhibitors, according to data.
Meanwhile, patients aged younger than 65 years who have never smoked demonstrated no apparent increased risk when receiving tofacitinib (Xeljanz, Pfizer), compared with TNF inhibitors, for up to 6 years of follow-up.
The data come from a post hoc analysis of the ORAL Surveillance trial.
“To ensure enough cardiovascular (CV) and malignancy events accrued in a

Patients aged 65 years and older or who have ever smoked are at higher risk for malignancies, major adverse cardiovascular events, myocardial infarction and all-cause death when using tofacitinib vs. TNF inhibitors, according to data.
Meanwhile, patients aged younger than 65 years who have never smoked demonstrated no apparent increased risk when receiving tofacitinib (Xeljanz, Pfizer), compared with TNF inhibitors, for up to 6 years of follow-up.
The data come from a post hoc analysis of the ORAL Surveillance trial.
“To ensure enough cardiovascular (CV) and malignancy events accrued in a